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MRI is the cornerstone of the diagnosis of multiple sclerosis (MS), and in recent years it was 
advocated for the follow up of the efficacy of the ever-growing number of disease modifying 
treatments (DMT).  While in the clinical practice the most important biomarkers are still the T2 and 
T1 enhancing lesion burden, clinical studies are already utilising atrophy estimation. These measures 
cover a vast majority of MS pathology, namely the perivenular inflammation and gliosis in the white 
matter lesions as well as grey matter pathology.  However, neither lesion burden nor atrophy is 
specific to the underlying pathology and both of these measures neglect to show the detrimental 
processes of the normal appearing white matter (NAWM). Quantitative MRI approaches could be of 
use to describe the various aspects of underlying pathological changes. In particular, various 
parameters estimated from diffusion tensor imaging (DTI) have been shown to correlate with 
demyelination and axonal loss in the white matter.  
In this issue of the European Journal of Neurology, Zivadinov et al. in a prospective, observational, 
longitudinal study investigated various diffusion parameters in the NAWM and in the thalamus as 
potential biomarkers to monitor the effectivity of dimethyl-fumarate in treating relapsing remitting 
MS patients [1]. They acquired diffusion data at two different field strengths and in thirty non-
collinear diffusion directions. There were three important results of the study: (i) At baseline, there 
was an extensive white matter disintegration in MS patients not only restricted to lesions, but also 
affecting the vast majority of the NAWM too. (ii) Over a 24-month follow-up period, there was no 
significant change in diffusion parameters in both healthy and MS patients alike. (iii) In a comparison 
of the two groups, MS patients showed slower deterioration of diffusion parameters compared to 
the healthy controls.  
A conclusion one could draw from the first two results could be that the therapy stopped the 
disintegration of the white matter and also the thalamus in MS. This is indicated by the significant 
intergroup differences, which did not further deteriorate when patients were on treatment. 
However, an alternative conclusion could be that changes in the diffusion parameters occur much 
slower than the time allowed for the follow-up period of the study. This conclusion is however made 
unlikely, considering that the rate of change in diffusion parameters was different between the two 
groups.  
This pioneering study calls attention to several outstanding questions, which need to be considered 
in future investigations. 
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1. What are the appropriate parameters necessary in order to acquire diffusion data? Diffusion 
tensor imaging was shown to have good reproducibility over various vendors and field 
strengths [2, 3]. In regard to the number of diffusion directions needed, former theoretical 
analyses and simulations made suggestions [4], but real life data especially of patients and in 
regions of specific interest for analysis (thalamus, white matter skeleton) is still sparse. Due 
to the duration of high diffusion direction studies, these questions are critical and the 
utilisation of novel techniques, such as multiband acquisitions should be investigated.  
2. The effect of biological factors on brain diffusion parameters (e.g. hydration, caffeine 
consumption, menstrual cycle etc.) should be understood. Special attention should be given 
when considering the effects of drugs, for example mega-dose steroid treatment. The anti-
inflammatory effect of DMTs could result in similar effect as in case of brain volume, termed 
pseudo-atrophy. Conversely, acute relapses may also have an effect on diffusion parameters 
outside the lesions.  
3. The natural course of the disease is not well known in terms of diffusion alterations, but the 
acquisition of such data is not straightforward given the increasing number of established 
effective therapies [5]. In large population studies, the stable and clinically (or other MRI 
parameter-wise) deteriorating patients should at the very least be investigated in order to 
learn about the magnitude of diffusion parameter changes.  
4. The relationship of diffusion parameters to clinical disability and cognitive dysfunction 
should be analysed. While lesion load and disability has only modest correlation, known as 
the clinico-radiological paradox [6, 7], the correlation of disability with brain atrophy seems 
to be stronger [8]. However, the contribution of various MRI parameters (lesion load, 
cortical and subcortical brain atrophy, diffusion alterations etc.) to clinical and cognitive 
dysfunction has not been analysed systematically. Special attention needs to be paid to the 
possible interrelatedness of the changes in these parameters [9]. 
5. Finally, the outstanding question is if diffusion is a sensitive enough biomarker to enter the 
world of clinical trials and everyday clinical practice. In order to do this, easy to implement 
and easy to interpret analysis approaches, usable on a single subject level should be 
developed.  
Zivadinov’s study contributes significantly to the above listed outstanding issues, may trigger further 
research and have implications for the design of future clinical trials. 
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